Cui Jiujie, Jiao Feng, Li Qi, Wang Zheng, Fu Deliang, Liang Jun, Liang Houjie, Xia Tingyi, Zhang Tao, Zhang Yang, Dai Guanghai, Zhang Zhihong, Wang Jian, Bai Yongrui, Bai Yuxian, Bi Feng, Chen Donghui, Cao Dan, Chen Jie, Fang Weijia, Gao Yong, Guo Jianwei, Hao Jihui, Hua Haiqing, Huang Xinyu, Liu Wenchao, Liu Xiufeng, Li Da, Li Ji, Li Enxiao, Li Zhiwei, Pan Hongming, Shen Lin, Sun Yongwei, Tao Min, Wang Chengfeng, Wang Fenghua, Xiong Jianping, Zhang Taiping, Zhang Xuebin, Zhan Xianbao, Zheng Leizhen, Ren Gang, Zhang Tingting, Zhou Jun, Ma Qingyong, Qin Shukui, Hao Chunyi, Wang Liwei
Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Department of Medical Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
J Natl Cancer Cent. 2022 Aug 23;2(4):205-215. doi: 10.1016/j.jncc.2022.08.006. eCollection 2022 Dec.
Pancreatic cancer is one of the leading causes of cancer-related mortality in both developed and developing countries. The incidence of pancreatic cancer in China accounts for about a quater of the global incidence, and the epidemiological characteristics and therapeutic strategies differ due to social, economic, cultural, environmental, and public health factors. Non-domestic guidelines do not reflect the clinicopathologic characteristics and treatment patterns of Chinese patients. Thus, in 2018, the Chinese Society of Clinical Oncology (CSCO) organized a panel of senior experts from all sub-specialties within the field of pancreatic oncology to compile the Chinese guidelines for the diagnosis and treatment of pancreatic cancer. The guidelines were made based on both the Western and Eastern clinical evidence and updated every one or two years. The experts made consensus judgments and classified evidence-based recommendations into various grades according to the regional differences, the accessibility of diagnostic and treatment resources, and health economic indexes in China. Here we present the latest version of the guidelines, which covers the diagnosis, treatment, and follow-up of pancreatic cancer. The guidelines might standardize the diagnosis and treatment of pancreatic cancer in China and will encourage oncologists to design and conduct more clinical trials about pancreatic cancer.
胰腺癌是发达国家和发展中国家癌症相关死亡的主要原因之一。中国胰腺癌的发病率约占全球发病率的四分之一，由于社会、经济、文化、环境和公共卫生因素，其流行病学特征和治疗策略存在差异。国外指南不能反映中国患者的临床病理特征和治疗模式。因此，2018年，中国临床肿瘤学会（CSCO）组织了胰腺癌领域各亚专业的资深专家小组，编写了《中国胰腺癌诊疗指南》。该指南基于东西方临床证据制定，每1至2年更新一次。专家们进行了共识判断，并根据中国的地区差异、诊断和治疗资源的可及性以及卫生经济指标，将循证推荐分为不同等级。在此，我们展示该指南的最新版本，其涵盖了胰腺癌的诊断、治疗及随访。该指南可能会规范中国胰腺癌的诊断和治疗，并将鼓励肿瘤学家设计和开展更多关于胰腺癌的临床试验。
